TRC102
1 product
1 abstract
Abstract
Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.Org: Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Cancer Therapy Evaluation Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute of the National Institutes of Health, Bethesda, MD, Clinical Pharmacodynamic Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Investigational Drug Branch, Clinical Pharmacodynamic Biomarker Program, Clinical Pharmacodynamics Biomarker Program,
Product
TRC102 + Temozolomide